SCHEMBL5502159

SCHEMBL5502159

CC(=O)OC[C@H]1O[C@@H](n2cnc3c(Cl)nc(OCCc4ccc(Cl)cc4)nc32)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.70
LMNA P02545 1/20 0.70
TP53 P04637 1/20 0.70
MAPT P10636 1/20 0.70
TDP1 Q9NUW8 1/20 0.70
ADORA2A P29274 9/20 0.52
ADORA2B P29275 8/20 0.52
ADORA1 P30542 3/20 0.52
ACHE P22303 4/20 0.49
PRKAB2 O43741 1/20 0.48
PRKAG1 P54619 1/20 0.48
PRKAA2 P54646 1/20 0.48
PRKAA1 Q13131 1/20 0.48
PRKAG3 Q9UGI9 1/20 0.48
PRKAG2 Q9UGJ0 1/20 0.48
PRKAB1 Q9Y478 1/20 0.48
ADORA3 P0DMS8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5494121 0.88 LMNA (0.75) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL5500120 0.85 LMNA (0.72) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL5497987 0.84 ALDH1A1 (0.68) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL5501249 0.83 ALDH1A1 (0.62) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL5496942 0.83 LMNA (0.66) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL24371902 0.83 LMNA (1.00) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL13012214 0.83 LMNA (1.00) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL21798516 0.83 LMNA (1.00) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL22826797 0.83 LMNA (1.00) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL8819179 0.83 ALDH1A1 (0.85) ALDH1A1LMNATP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446413-A4 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES KING PHARMACEUTICALS RES & DEV (US) 2007-10-17 EP disclosed
US-6951932-B2 Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2005-10-04 US disclosed
EP-1446413-A1 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES King Pharmaceuticals Research and Development Inc. (US) 2004-08-18 EP disclosed
US-20030199686-A1 Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-10-23 US disclosed
WO-2003035662-A1 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199686-A1 Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines AMPD2, ADAR, ADA ALDH1A1 2143/4885LMNA 2588/4885TP53 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.